IDWeek 2021: Clinical Impact of New Data*

Download All
September 29 - October 3, 2021; Virtual
Get the latest data from IDWeek 2021 on practical management strategies and the latest data for HIV, C difficile, COVID-19, and vaccine-preventable diseases. Explore key studies from this important annual conference in the on-demand webinars, Capsule Summaries, and ClinicalThought expert commentaries. Share the downloadable slidesets with colleagues.

IDWeek 2021: Clinical Impact of New HIV Data

Capsule Summary Slidesets

Data from 1998-2018 suggest interventions are needed to reduce disparities in mortality among women and Black people.

Released: October 3, 2021

Data showed increases in BMI in all groups but no marked differences between regimens at Week 144 for treatment-emergent diabetes or hypertension or for changes in BMI.

Released: October 3, 2021

Active surveillance demonstrates that introduction of PCV13 led to declines in IPD in people with and without HIV and suggests benefits of newly approved higher valency PCVs.

Released: October 7, 2021

In real-world cohort, early weight gain following ART initiation associated with excessive weight gain at 2 years.

Released: October 3, 2021

Limited treatment-emergent lenacapavir resistance occurred after 28 weeks of oral or subcutaneous lenacapavir plus FTC/TAF.

Released: October 5, 2021

Analysis of international registry data through January 2021 shows that prevalence of birth defects with prenatal DTG is comparable with that seen in the general population.

Released: October 5, 2021

Pilot study results support feasibility as first-line therapy in a test-and-treat setting, including in patients with a high HIV-1 RNA at baseline (ie, >500,000 copies/mL).

Released: October 3, 2021

In a web-based survey, US participants who reported being informed of the U=U campaign had more favorable health outcomes regarding self-reported viral suppression, optimal sexual and mental health, and treatment satisfaction vs those not informed of U=U.

Released: October 5, 2021

Despite increasing PrEP uptake in people at high-risk of HIV acquisition in the United States, overall use remains low, especially in populations such as those insured by Medicaid, young adults, and women.

Released: October 4, 2021

Switching to DTG/3TC continues to show high levels of virologic suppression, favorable safety and tolerability, and a high barrier to resistance through 3 years.

Released: October 5, 2021

Leaving the CCO site

You are now leaving the CCO site. The new destination site may have different terms of use and privacy policy.


Cookie Settings